Pharmaceutical Executive
A major theme permeating our June issue is pharma's reputation issue and how the COVID-19 crisis should be driving new ways executives lead their companies now-and on the other side.
Lisa Henderson
This month is our Annual Pharma 50 issue, where we list, with our data partner EvaluatePharma, the top 50 companies according to drug sales for the past year. This is a big deal and, generally, is the all-time, most-read article on our website each year.
Pharmaceutical company success by brand revenue is a milestone, don’t get me wrong, and this year it will still garner massive amounts of attention. But it’s June. 2020. As we creep out of the pandemic. So this month, we also address our industry in regard to agile leadership and how the COVID-19 crisis should be influencing the ways executives lead their companies and the industry now-and on the other side.
The last time I heard Lieutenant General (Ret) Rick Lynch, US Army, speak was at an “Adapt or Die” meeting held by Bob Jansen, CEO of Zensights and a Pharmaceutical Executive Editorial Advisory Board member, over two years ago (see here).
Rick Lynch and Bob Jansen
At these meetings, Jansen brings together pharma and healthcare executives to learn what leadership looks like from inside those industries, as well as outside from Lynch’s formidable military experience and masterful viewpoint. I had the opportunity to listen again to Lynch in late May, when Jansen brought together a large group-virtually, of course-to discuss leadership through the COVID-19 health crisis.
Lynch began with the current state of affairs in our lives…it’s volatile, uncertain, and ambiguous. The task for agile and adaptive leaders is to respond appropriately in three manageable phases. The first phase is survival, while sustaining some level of forward movement; the second is recovery; and the third, preparation.
For the first phase, Lynch stressed to the leaders to look for the opportunities and not the obstacles. “Master the technology. We all are on Zoom now. Understand the technology and take steps to use it better,” he said. Lynch noted that the crisis is also an opportunity to learn about other views (read a book, suggests Lynch) or take time to think, since you aren’t going from meeting to meeting. And, most of all, spend this found time with your families.
Recovery is the next stage, and one that many have started. Some CEOs present at a recent roundtable that Pharmaceutical Executive hosted on behalf of our parent company, MJH Life Sciences, are looking at their operations with a new eye toward changing the balance of work-from-home and office schedules or reducing their commercial real estate footprint. They are doing exactly what Lynch suggests: visualize the future, what it looks like, and how you get there.
The final stage is preparation. Once the crisis has passed and the smoke has cleared, said Lynch, you have to prepare to preclude it from happening again. “Capture your lessons learned and put them into practice. What worked, what didn’t work,” he advised. “Because it will happen again.”
Part of Lynch and Jansen’s mission, established when they first met, was figuring out how pharma could repair its sagging reputation and public perception, much like the military achieved post-Vietnam. The answer was adaptive leadership. Right now, many pharma leaders sense this is a time that could change the public’s negative image of “big pharma.” See our Senior Editor Elaine Quilici’s article, where she touches on the emerging sentiments around just that. Our Finance Columnist Barbara Ryan also addresses the reputation issue, asking pharma and biotech leaders to take the reins.
Lynch said, “There is a great opportunity to be the heroes of the world, with the right therapy, the right vaccine. But everyone is looking at you with suspect. Take advantage of this moment, but you must do it with integrity and transparency.”
He noted that the public is closely watching how pharma invests in its resources. Is it appropriate or not? Are companies saying one thing, but doing another? Are you not only doing the right things, but doing things right?
Now is the time to check-in and ensure your vision, leadership, and moral compass are aligned.
Lisa Henderson is Editor-in-Chief of Pharm Exec. She can be reached at lhenderson@mjhlifesciences.com. Follow Lisa on Twitter: @trialsonline
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.